Kazia Therapeutics Limited
KZIA
$3.30
-$0.2395-6.77%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 18,883.33% | 18,966.67% | -- | -83.33% | -91.78% |
| Total Revenue | 272,116.67% | 271,933.33% | -- | -83.33% | -91.78% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 272,116.67% | 271,933.33% | -- | -83.33% | -91.78% |
| SG&A Expenses | 54.11% | 38.50% | 21.29% | 33.48% | 52.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.08% | -2.58% | -27.24% | -20.16% | -11.86% |
| Operating Income | -15.04% | 7.37% | 27.24% | 20.15% | 11.82% |
| Income Before Tax | -27.38% | 10.71% | 40.29% | 32.87% | 24.33% |
| Income Tax Expenses | 2.58% | -14.44% | -40.26% | 9.25% | 32.12% |
| Earnings from Continuing Operations | -27.77% | 10.96% | 40.88% | 33.13% | 24.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.77% | 10.96% | 40.88% | 33.13% | 24.21% |
| EBIT | -15.04% | 7.37% | 27.24% | 20.15% | 11.82% |
| EBITDA | -16.52% | 7.65% | 29.05% | 21.22% | 12.19% |
| EPS Basic | 21.91% | 47.67% | 64.51% | 51.94% | 39.16% |
| Normalized Basic EPS | 30.20% | 45.32% | 56.25% | 44.23% | 32.02% |
| EPS Diluted | 21.91% | 47.67% | 64.51% | 51.93% | 39.16% |
| Normalized Diluted EPS | 30.20% | 45.32% | 56.25% | 44.23% | 32.02% |
| Average Basic Shares Outstanding | 43.08% | 52.98% | 66.09% | 52.94% | 39.12% |
| Average Diluted Shares Outstanding | 43.32% | 53.26% | 66.43% | 53.05% | 39.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |